CSTL: Castle Biosciences, Inc. Stock

by  •  • Comments Off on CSTL: Castle Biosciences, Inc. Stock

SIC 8071 – Medical Laboratories

Valuation
Market Cap ($M) 581.81
Enterprise Value ($M) 482.97
Book Value ($M) 391.27
Book Value / Share 14.18
Price / Book 1.49
NCAV ($M) 233.56
NCAV / Share 8.47
Price / NCAV 2.49

Profitability (mra)
Return on Invested Capital (ROIC) -0.14
Return on Assets (ROA) -0.13
Return on Equity (ROE) -0.15

Liquidity (mrq)
Quick Ratio 6.04
Current Ratio 6.20

Balance Sheet (mrq) ($M)
Current Assets 295.63
Assets 453.34
Liabilities 62.07
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 219.79
Operating Income -67.98
Net Income -57.47
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -5.63
Cash from Investing -16.18
Cash from Financing -2.30

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G Granahan Investment Management Inc/ma 8.05
02-13 13G Principal Global Investors 5.89
02-13 13G/A Vanguard Group Inc 5.43 4.94
02-09 13G/A Wasatch Advisors Inc
01-25 13G/A BlackRock Inc. 8.50 7.51

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-01 39,560 221,256 17.88
2024-04-30 36,750 132,884 27.66
2024-04-29 45,473 63,251 71.89
2024-04-26 19,213 45,272 42.44

(click for more detail)

Similar Companies
BDSX – Biodesix, Inc. CDNA – CareDx, Inc
CNTG – Centogene N.V. FLGT – Fulgent Genetics, Inc.
PSNL – Personalis, Inc.


Financial data and stock pages provided by
Fintel.io